Amgen (AMGN) shares fell 10% to $394.38 in Tuesday trading, driven by a sector-wide repricing of Lp(a) cholesterol drugs following Novartis's failed pelacarsen trial. Despite Amgen posting positive Phase 3 results for its IMDELLTRA study in small cell lung cancer on the same morning, investors...
Amgen Inc. (NASDAQ: AMGN) reported significant findings from a prespecified secondary analysis of the Phase 3 VESALIUS-CV trial, indicating that its PCSK9 inhibitor, Repatha, reduced the risk of all-cause mortality by 20% in high-risk adults without prior heart attacks or strokes. The study, which followed...
Amgen Inc. (AMGN) shares closed near an all-time high of $432.42 on August 28, trading above the consensus analyst price target after a strong Q2 report. The company reported quarterly revenue of $10.05 billion, marking the first time it crossed the $10 billion threshold, with...
Amgen Inc. (NASDAQ: AMGN) saw increased institutional interest in the first quarter of 2026, led by Bessemer Group Inc., which boosted its holdings by 9.9% to own 32,013 shares valued at $11.26 million. Other major funds including Robeco Institutional Asset Management B.V., Fideuram Intesa Sanpaolo...
Fort Washington Investment Advisors Inc. increased its stake in Amgen Inc. (NASDAQ:AMGN) by 5.2% during the first quarter, purchasing an additional 4,559 shares to hold a total position of 92,090 shares valued at $32.4 million. This move aligns with several other institutional investors who recently...
